{"entity":{"id":"nct06861088","kind":"trial","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Kinisoquin™ in pancreatic ductal adenocarcinoma, run by Quercis Pharma AG, now recruiting.","summary":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer is a phase 3 interventional study registered as NCT06861088 by Quercis Pharma AG, with 480 participants planned, started 2025-12-19 and due to reach its primary completion in 2027-10-31. Interventions recorded: Kinisoquin™ and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06861088","url":"https://clinicaltrials.gov/study/NCT06861088"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06861088","phase":"3","setting":"A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer (CATIQ P3)","sponsor":"Quercis Pharma AG","enrolled":480,"outcomes":[]},"route":"/trials/nct06861088/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}